Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb: Enfamil infant formula drives U.S. nutritionals sales up 5% to $267 mil. in the second quarter, Bristol reports July 28. The product also spurred international nutritionals results up 10% to $281 mil. to lead worldwide nutritionals business to $548 mil. in total revenues, up 7% over the prior-year period. The unit was a strong performer for Bristol's overall business, which recorded relatively flat sales of $4.9 bil. and an 89% increase in net earnings to $991 mil. The company's consumer medicines sales declined 16% to $57 mil.; Bristol recently announced plans to divest the unit to Novartis, a transaction expected to close by the end of the third quarter (1"The Tan Sheet" July 18, 2005, p. 3)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS098490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel